AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35008008 — intervention group
Group type: COMPARATOR
Intervention: IVIG 10% every 3 or 4 weeks
Number of subjects: 95
Study 34476095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation (menaquinone-7, 360 µg daily)
Number of subjects: 48
Study 34476095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33564963 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion post-exercise
Number of subjects: 8
Study 33564963 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage post-exercise
Number of subjects: 8
Study 32716645 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial video game for 30 minutes
Number of subjects: 60
Study 32716645 — intervention group
Group type: COMPARATOR
Intervention: Neutral video game for 30 minutes
Number of subjects: 60
Study 34175554 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-related stressor
Number of subjects: 52
Study 34175554 — intervention group
Group type: COMPARATOR
Intervention: General stressor
Number of subjects: 52
Study 32363743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 14943
Study 32363743 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 14943
Study 34115697 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity Loss 40% (VL40)
Number of subjects: 30
Study 34115697 — intervention group
Group type: COMPARATOR
Intervention: Velocity Loss 20% (VL20)
Number of subjects: 30
Study 34896068 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured recommendations and electronic tracking (post-intervention)
Number of subjects: 1301
Study 34896068 — intervention group
Group type: COMPARATOR
Intervention: No structured recommendations (pre-intervention)
Number of subjects: 1301
Study 33236826 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt bath + UVB
Number of subjects: 2105
Study 33236826 — intervention group
Group type: COMPARATOR
Intervention: UVB alone
Number of subjects: 2105
Study 34473544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg once every 2 weeks)
Number of subjects: 316
Study 34473544 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM 1000 mg/m2 for 30 minutes on days 1, 8, and 15) or Pegylated Liposomal Doxorubicin (PLD 50 mg/m2 once every 4 weeks)
Number of subjects: 316
Study 34473544 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM) or Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 316
Study 33399989 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 96
Study 33399989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 33741048 — intervention group
Group type: EXPERIMENTAL
Intervention: Order set change and facilitation training (2-day workshop with antibiotic stewardship teams)
Number of subjects: 0
Study 32937045 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg body weight) plus standard therapy
Number of subjects: 448
Study 32937045 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 448
Study 33597056 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g milk protein (MILK)
Number of subjects: 36
Study 33597056 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g wheat protein (WHEAT)
Number of subjects: 36
Study 33597056 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g blend of 15 g wheat plus 15 g milk protein (WHEAT+MILK)
Number of subjects: 36
Study 33040782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuling Wendan Decoction combined with flunarizine
Number of subjects: 96
Study 33040782 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 96
Study 35419083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT enterography (CTE) based on modified guided image filtering (GIF) algorithm
Number of subjects: 120
Study 35419083 — intervention group
Group type: COMPARATOR
Intervention: Routine CT examination (Control group)
Number of subjects: 120
Study 35419083 — intervention group
Group type: EXPERIMENTAL
Intervention: CTE in the diagnosis of UC and CD
Number of subjects: 120
Study 34428740 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 95
Study 34428740 — intervention group
Group type: COMPARATOR
Intervention: Non-Metformin
Number of subjects: 95
Study 35644335 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic IVC filters
Number of subjects: 100
Study 35644335 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation therapy delay
Number of subjects: 100
Study 35644335 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of filter left in situ
Number of subjects: 100
Study 32893536 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinye Baidu Granules, 10 g/time, three times a day for 5 days
Number of subjects: 606
Study 32893536 — intervention group
Group type: COMPARATOR
Intervention: Compound Shuanghua Granules placebo, 6 g/time, four times a day for 5 days
Number of subjects: 606
Study 32893536 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinye Baidu Granules
Number of subjects: 606
Study 32893536 — intervention group
Group type: COMPARATOR
Intervention: Compound Shuanghua Granules
Number of subjects: 606
Study 35227365 — intervention group
Group type: EXPERIMENTAL
Intervention: High aesthetic-color flyer
Number of subjects: 204
Study 35227365 — intervention group
Group type: EXPERIMENTAL
Intervention: High aesthetic-black-and-white flyer
Number of subjects: 204
Study 35227365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low aesthetic-color flyer
Number of subjects: 204
Study 35227365 — intervention group
Group type: COMPARATOR
Intervention: Low aesthetic-black-and-white flyer
Number of subjects: 204
Study 35689729 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT + AAT
Number of subjects: 33
Study 35689729 — intervention group
Group type: COMPARATOR
Intervention: TF-CBT alone
Number of subjects: 33
Study 35689729 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT + AAT and TF-CBT alone
Number of subjects: 33
Study 34001414 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 35
Study 34001414 — intervention group
Group type: COMPARATOR
Intervention: Nitrous Oxide (N2O)
Number of subjects: 35
Study 32723754 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Standard Educational Care (MI+SEC)
Number of subjects: 47
Study 32723754 — intervention group
Group type: COMPARATOR
Intervention: Standard Educational Care (SEC)
Number of subjects: 47
Study 35841043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation support for PainManager CDS tool
Number of subjects: 0
Study 35841043 — intervention group
Group type: EXPERIMENTAL
Intervention: PainManager CDS tool
Number of subjects: 0
Study 33485608 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Depo-Provera (n = 24)
Number of subjects: 42
Study 33485608 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Depo-Provera (n = 9)
Number of subjects: 42
Study 33485608 — intervention group
Group type: COMPARATOR
Intervention: Depo-SubQ Provera 104 (two injections, n = 9)
Number of subjects: 42
Study 32209897 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic surgery (SPLS)
Number of subjects: 388
Study 32209897 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic surgery (MPLS)
Number of subjects: 388
Study 32524605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package including promotional materials, education for traditional birth attendants, and provider capacity building.
Number of subjects: 24412
Study 32524605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 24412
Study 36357289 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative probe (asking participants to compare which vaccine to take)
Number of subjects: 1736
Study 36357289 — intervention group
Group type: COMPARATOR
Intervention: Deliberative probe (asking participants whether they would like to take the vaccine)
Number of subjects: 1736
Study 36357289 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative probe among Pro-Trump Republicans
Number of subjects: 1736
Study 34007017 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + ADT
Number of subjects: 177
Study 34007017 — intervention group
Group type: COMPARATOR
Intervention: Control (ADT only)
Number of subjects: 177
Study 32495329 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP), 6-month intervention, 3 times a week, 45 minutes per session
Number of subjects: 20
Study 32495329 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 20
Study 32495329 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 33759701 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine and Caffeine (CR-CAF)
Number of subjects: 28
Study 33759701 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 28
Study 33759701 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (CAF)
Number of subjects: 28
Study 33759701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 28
Study 33893738 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 99
Study 33893738 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 99
Study 35393245 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium score PSN
Number of subjects: 3556
Study 35393245 — intervention group
Group type: COMPARATOR
Intervention: Contemporary PTP score incorporating calcium score and risk factors
Number of subjects: 3556
Study 34588952 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day istradefylline
Number of subjects: 40
Study 34588952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33269394 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of safe live microbes
Number of subjects: 0
Study 33269394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recommendations for live microbes
Number of subjects: 0
Study 35684031 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders (MNP)
Number of subjects: 54
Study 35684031 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 54
Study 35684031 — intervention group
Group type: COMPARATOR
Intervention: Fortified food (FF)
Number of subjects: 54
Study 34224382 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent optimization using high-definition intravascular ultrasound (HD-IVUS)
Number of subjects: 29
Study 34224382 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided stenting (AGS)
Number of subjects: 29
Study 32472836 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Number of subjects: 35
Study 32472836 — intervention group
Group type: COMPARATOR
Intervention: Amber light therapy
Number of subjects: 35
Study 34802879 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum combination chemotherapy plus pembrolizumab
Number of subjects: 422
Study 34802879 — intervention group
Group type: COMPARATOR
Intervention: Platinum combination chemotherapy plus nivolumab and ipilimumab
Number of subjects: 422
Study 34753515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 120
Study 34753515 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 120
Study 36214414 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Parenting for Bereaved Families program (RPBF)
Number of subjects: 74
Study 36214414 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 74
Study 32673002 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate Practice (DP) workshop
Number of subjects: 88
Study 32673002 — intervention group
Group type: COMPARATOR
Intervention: Control workshop (traditional non-DP)
Number of subjects: 88
Study 36411723 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced tacrolimus (EVR+rTAC)
Number of subjects: 117
Study 36411723 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus (sTAC)
Number of subjects: 117
Study 32049191 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic substance (Frutooligossacaride 6g, Lactobacillus paracasei LPC‐31 10^9 to 10^8 UFC, Lactobacillus rhamnosus HN001 10^9 to 10^8 UFC, Lactobacillus acidophilus NCFM 10^9 to 10^8 UFC, Bifidobacterium lactis HN019 10^9 to 10^8 UFC)
Number of subjects: 49
Study 32049191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 35522626 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention for GPs including a workshop on appropriate prescribing of BZDs, tapering-off long-term BZD use, monthly BZD prescription feedback, and access to a support web page.
Number of subjects: 749
Study 35522626 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 749
Study 35522626 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention for GPs.
Number of subjects: 749
Study 33860592 — intervention group
Group type: EXPERIMENTAL
Intervention: Milestone Communication Approach (MCA)
Number of subjects: 174
Study 33860592 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 174
Study 36075233 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA2001 (0.5 mL; 33 antigen units per dose)
Number of subjects: 4017
Study 36075233 — intervention group
Group type: COMPARATOR
Intervention: ChAdOx1-S (0.5 mL; 2.5 x 10^8 infectious units per dose)
Number of subjects: 4017
Study 36075233 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA2001 (open-label for participants aged 18-29 years)
Number of subjects: 4017
Study 36075233 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA2001 (randomised for participants aged 30 years and older)
Number of subjects: 4017
Study 33673068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 0
Study 33673068 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Needle Electrolysis (PNE)
Number of subjects: 0
Study 33622700 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary KPro
Number of subjects: 82
Study 33622700 — intervention group
Group type: COMPARATOR
Intervention: Secondary KPro
Number of subjects: 82
Study 34413795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 123
Study 34413795 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 123
Study 34413795 — intervention group
Group type: COMPARATOR
Intervention: Psycho-Education (PE)
Number of subjects: 123
Study 32563539 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 0
Study 32563539 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 0
Study 35300932 — intervention group
Group type: EXPERIMENTAL
Intervention: ERR-10 days
Number of subjects: 0
Study 35300932 — intervention group
Group type: COMPARATOR
Intervention: ERR-14 days
Number of subjects: 0
Study 35300932 — intervention group
Group type: EXPERIMENTAL
Intervention: NERR-14 days
Number of subjects: 0
Study 35300932 — intervention group
Group type: COMPARATOR
Intervention: NERR-21 days
Number of subjects: 0
Study 32160504 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided subacromial corticosteroid and LA injection
Number of subjects: 29
Study 32160504 — intervention group
Group type: COMPARATOR
Intervention: Blind subacromial corticosteroid and LA injection
Number of subjects: 29
Study 35395383 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Glasgow prognostic score (mGPS) based on plasma C-reactive protein (CRP) and albumin levels.
Number of subjects: 0
Study 35395383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline muscle or adipose tissue parameters during 12 weeks of treatment.
Number of subjects: 0
Study 35395383 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern Cooperative Oncology Group performance status together with CRP or mGPS.
Number of subjects: 0
Study 33023185 — intervention group
Group type: EXPERIMENTAL
Intervention: rTSST-1v vaccine
Number of subjects: 34
Study 33023185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 34218960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hillchol
Number of subjects: 560
Study 34218960 — intervention group
Group type: COMPARATOR
Intervention: Shanchol
Number of subjects: 560
Study 32027441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (280 patients)
Number of subjects: 418
Study 32027441 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (138 patients)
Number of subjects: 418
Study 34802352 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 99
Study 34802352 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 99
Study 33895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for patellar fractures; 23 cases treated nonoperatively.
Number of subjects: 2954
Study 33895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment for patellar fractures; 9 cases treated operatively.
Number of subjects: 2954
Study 33895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative HSS score compared to postoperative HSS score.
Number of subjects: 2954
Study 33895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications after treatment for patellar fractures.
Number of subjects: 2954
Study 33895032 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment results based on treatment method and fracture type.
Number of subjects: 2954
Study 32967495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the intersphincteric fistula tract (LIFT)
Number of subjects: 90
Study 32967495 — intervention group
Group type: COMPARATOR
Intervention: Traditional anal fistulectomy
Number of subjects: 90
Study 36006761 — intervention group
Group type: COMPARATOR
Intervention: Single-vision contact lenses (SVCL)
Number of subjects: 95
Study 36006761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended depth of focus contact lenses (EDOF)
Number of subjects: 95
Study 36006761 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSight® contact lenses
Number of subjects: 95
Study 32222935 — intervention group
Group type: EXPERIMENTAL
Intervention: SALAS score assessment during the entire operation (group A)
Number of subjects: 20
Study 32222935 — intervention group
Group type: EXPERIMENTAL
Intervention: SALAS score assessment during the 2nd and 3rd quartile of the operation (group B)
Number of subjects: 20
Study 32222935 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability of the SALAS score
Number of subjects: 20
Study 32222935 — intervention group
Group type: COMPARATOR
Intervention: Correlation between operation time and SALAS score
Number of subjects: 20
Study 34350055 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe clearance rehabilitative slippers (top-weighted with a lead bead of 200, 300, or 400 g), worn for 10-20 min, 1-3 days/week for 12 months.
Number of subjects: 59
Study 34350055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 59
Study 32583931 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright light therapy (BLT) for 30 minutes in the morning for 14 consecutive days
Number of subjects: 41
Study 32583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light bright light therapy (BLT) for 30 minutes in the morning for 14 consecutive days
Number of subjects: 41
Study 32583931 — intervention group
Group type: COMPARATOR
Intervention: No bright light therapy (no-BLT)
Number of subjects: 41
Study 35156458 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 42
Study 35156458 — intervention group
Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 42
Study 33092901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin A
Number of subjects: 52
Study 33092901 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 52
Study 35805529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program and high-protein supplementation (1.3 g/kg BW/day)
Number of subjects: 60
Study 35805529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein supplementation (1.3 g/kg BW/day)
Number of subjects: 60
Study 35805529 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily routine)
Number of subjects: 60
Study 33238991 — intervention group
Group type: EXPERIMENTAL
Intervention: eASCs (Cx611) administered intravenously at a dose of 160 million cells (2 million cells/mL, total volume 80 mL) on Day 1 and Day 3
Number of subjects: 180
Study 33238991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ringer Lactate) administered intravenously at the same quantity (total volume of 80 mL) and schedule as the active treatment
Number of subjects: 180
Study 35023356 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) tool (Anticoagulation Choice)
Number of subjects: 922
Study 35023356 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 922
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Hand-washing promotion (education activities, sometimes with provision of soap) in child day-care centres or schools
Number of subjects: 84966
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Hand-washing promotion in LMICs
Number of subjects: 84966
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Hand-washing promotion among communities in LMICs
Number of subjects: 84966
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Hand-washing promotion with soap provided
Number of subjects: 84966
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Education only (no soap provided)
Number of subjects: 84966
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Hand-washing promotion in a hospital among a high-risk population
Number of subjects: 84966
Study 33539552 — intervention group
Group type: COMPARATOR
Intervention: Hand-washing frequency in the hospital trial
Number of subjects: 84966
Study 32189061 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT (35 °C)
Number of subjects: 7
Study 32189061 — intervention group
Group type: EXPERIMENTAL
Intervention: TEMP (21 °C)
Number of subjects: 7